middle.news
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge in FY2025
3:38am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge in FY2025
3:38am on Saturday 30th of August, 2025 AEST
Key Points
FY2025 revenue from cell therapy products up 191%, led by Ryoncil launch
Ryoncil approved by FDA and commercially available since March 2025
Ongoing Phase 3 trials for chronic low back pain and label expansion for Ryoncil
REVASCOR progressing toward accelerated FDA approval for heart failure
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE